BioArctic expands portfolio with alpha-synuclein Brain Transporter project

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that the company is expanding its alpha-synuclein project portfolio. The new project, PD-BT2238, combines a selective alpha-synuclein oligomer targeting antibody with BioArctic’s proprietary Brain Transporter technology, to increase exposure of the antibody in the brain, with the aim of increasing efficacy of a potential treatment in Parkinson’s disease.

Parkinson’s disease is a neurodegenerative disorder that affects the nervous system. The first symptoms could be barely noticeable tremors of a hand or a leg. As the disease progresses, people may develop difficulties walking and talking, experience mental and behavioral changes such as sleep problems, depression, memory difficulties and fatigue.^[1] Today, several symptomatic treatments are available, but no disease modifying alternatives exists.

BioArctic’s aim is to develop an antibody treatment targeting soluble aggregated forms of alpha-synuclein, a protein that is genetically and neuropathologically linked to Parkinson’s disease and believed to be an important initiating factor in the disease development. The PD-BT2238 project is a second-generation alpha-synuclein antibody, combining an oligomer-selective alpha-synuclein antibody with BioArctic’s Brain Transporter technology, designed to improve brain exposure.

“BioArctics proprietary Brain Transporter technology has the opportunity to improve brain exposure and thereby the efficacy of biologic treatments for various neurodegenerative diseases. We are therefore very excited to also bring this technology into our Parkinson’s disease project portfolio,” says Gunilla Osswald, BioArctic’s CEO.

BioArctic’s alpha-synuclein frontrunner BAN0805 is currently in preparation for phase 2, while potential partnerships are being explored. Phase 1 data showed that BAN0805 was well tolerated, supporting continuation into phase 2 with once-monthly dosing.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.

For further information, please contact: 
Gunilla Osswald, CEO                                                                        
E-mail: gunilla.osswald@bioarctic.se                                              
Phone: +46 8 695 69 30

Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80